AstraZeneca Tagrisso Osimertinib 80mg

Description

Tagrisso 80mg What is Osimertinib?

Tagrisso 80mg contains osimertinib 80mg, a third generation epidermal growth factor receptor inhibitor (EGFR-TKI). The drug is used in the treatment of metastatic non-small cell lung cancer with positive EGFR mutations. The FDA first approved the drug in November 2015 and gave it full approval in 2017.

In 2018, osimertinib was recommended as a first-line treatment in similar cases. In the form of a once-daily pill, Tagrisso offers hope for significantly improving longevity and quality of life for patients with metastatic lung cancer.

2. Uses of Tagrisso 80mg

Tagrisso 80mg is used to treat the following patients:

• The patient was determined to have the “T790M mutation” through testing and had a doctor’s prescription to use this drug.
• In cases where patients with cancer have worsened or progressed despite undergoing previous treatments, there may be drugs that inhibit ‘EGFR’ (epidermal growth factor receptor). tare).

3. Usage and dosage of Tagrisso 80mg

3.1 How to use

Tagrisso 80mg is produced in the form of film-coated tablets, which can be taken orally and taken at the same time every day, with or without food.

For patients who have difficulty swallowing intact tablets, the tablets may be dissolved in 50 ml of carbonate-free water. The tablet should be dropped into water without crushing, stirred until completely dissolved and taken immediately afterwards. Use another half glass of water to rinse the glass, making sure to drink the rest of the medicine and do not use any other liquid.

In case it is necessary to use via a nasogastric tube, the procedure is the same as above but only use 15 ml of water for each mixing and rinsing of the tube, for a total of 30 ml of water. The medicinal solution should be used and rinsed within 30 minutes after preparation.

3.2 Dosage

Treatment with Tagrisso 80mg should be carried out under the supervision of a doctor with expertise in cancer treatment.

Before starting treatment for advanced or metastatic non-small cell lung cancer (NSCLC), patients need to have their EGFR T790M mutation status determined through standard tests.

The recommended dosage is 80 mg osimertinib daily, continued until disease progression or unacceptable adverse toxic